New Drug for Rare Neuroendocrine Tumors Shows Durable Activity

(MedPage Today) — BERLIN — Belzutifan (Welireg) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm phase II trial, evidence that supported FDA’s recent approval in these very rare neuroendocrine tumors…